Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

In the Phase II MAIA lung cancer trial, THIO improved patients’ overall survival when taken in combination with Libtayo.

Study finds three new safe and effective drug regimens to fight multidrug-resistant TB. The treatments, which include recently discovered TB drugs, give new options for shorter, personalized treatment ...

and medical journals and associations. We only use quality, credible sources to ensure content accuracy and integrity. You can learn more about how we ensure our content is accurate and current by ...

As a doctor, I understand it is a critical issue and needs attention. To protect patients, even the World Health Organization has released guidelines on the quality of medical oxygen," Gopchade told ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Detailed results will be presented at an upcoming medical meeting and will be shared with regulatory ... research across diverse stages of skin cancer.” The potential use of Libtayo described above is ...

In interviews, Musk has mentioned using doctor-prescribed ketamine to alleviate periods of depression. He believes that managing his mental health is beneficial not only for his well-being but also ...